There is a need to specify the profile of subjective cognitive decline in preclinical Alzheimer’s disease (preAD).
Objectives:
To explore specific items of the Subjective Cognitive Decline Questionnaire (SCD-Q) that discriminate preAD from normal aging.
Methods:
68 cognitively normal older adults were classified as controls (n = 52) or preAD (n = 16) according to amyloid-β (Aβ) levels. An exploratory factor analysis and item analysis of the SCD-Q were performed. Informant reports of the SCD-Q were used to corroborate the findings of self-reports. One-year neuropsychological follow-up was available.
Results:
Four SCD-Q factors were extracted: EM-factor (episodic memory), A-factor (attention), O-factor (organization), and L-factor (language). PreAD reported a significantly higher decline in L-factor (F(1) = 6.49; p = 0.014) and A-factor (F(1) = 4.04; p = 0.049) compared to controls, and showed a higher frequency of perceived decline in SCD-Q items related with language and executive tasks (Sig-items.) Significant discriminative powers for Aβ-positivity were found for L-factor (AUC = 0.75; p = 0.003) and A-factor (AUC = 0.74; p = 0.004). Informants in the preAD group confirmed significantly higher scores in L-factor and Sig-items. A significant time×group interaction was found in the Semantic Fluency and Stroop tests, with the preAD group showing a decrease in performance at one-year.
Conclusions:
Our results suggest that SCD-Q items related with language and executive decline may help in prediction algorithms to detect preAD. Validation in an independent population is needed.
JackCR, AlbertM, KnopmanDS, McKhannGM, SperlingRA, CarrilloM, WilliamT, PhelpsCH (2011) Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 257–262.
2.
DuboisB, FeldmanHH, JacovaC, CummingsJL, DeKoskyST, Barberger-GateauP, DelacourteA, FrisoniG, FoxNC, DouglasG, GauthierS, HampelH, JichaGA, MeguroK, O’BrienJ, PasquierF, RobertP, RossorM, SallowayS, SarazinM, de SouzaLC, SternY, VisserPJ, ScheltensP (2010) Revising the definition of Alzheimer’s disease: A new lexicon. Lancet Neurol9, 1118–1127.
3.
SperlingRA, AisenPS, BeckettLA, BennettDA, CraftS, FaganAM, IwatsuboT, JackCRJr, KayeJ, MontineTJ, ParkDC, ReimanEM, RoweCC, SiemersE, SternY, YaffeK, CarrilloMC, ThiesB, Morrison-BogoradM, WagsterMV, PhelpsCH (2011) Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging and the Alzheimer’s Association workgroup. Alzheimers Dement7, 1–13.
4.
OhH, MorminoEC, MadisonC, HayengaA, SmiljicA, JagustWJ (2011) β-Amyloid affects frontal and posterior brain networks in normal aging. Neuroimage54, 1887–1895.
5.
MusiekES, HoltzmanDM (2015) Three dimensions of the Amyloid hypothesis: Time, space, and “wingmen”. Nat Neurosci18, 800–806.
6.
BennettDA, SchneiderJA, ArvanitakisZ, KellyJF, AggarwalNT, ShahRC, WilsonRS (2006) Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology66, 1837–1844.
7.
GalvinJE, PowlishtaK, WilkinsK, McKeelDWJr, XiongC, GrantE, StorandtM, MorrisJC (2005) Predictors of preclinical Alzheimer disease and dementia: A clinicopathological study. Arch Neurol62, 758–765.
8.
DuboisB, FeldmanHH, JacovaC, DekoskyST, Barberger-gateauP, CummingsJ, DelacourteD, GalaskoD, GauthierS, JichaG, MeguroK, O’BrienJ, PasquierF, RobertR, RossorM, SallowayS, SternY, VisserPJ (2007) Research criteria for the diagnosis of Alzheimer’s disease: Revising the NINCDS–ADRDA criteria. Lancet Neurol6, 734–746.
9.
JessenF (2014) Subjective and objective cognitive decline at the pre-dementia stage of Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci264, 3–7.
10.
JessenF, AmariglioRE, Van BoxtelM, BretelerM, CeccaldiM, ChetelatG, DuboisB, DufouilC, EllisKA, van der FlierWM, GlodzikL, van HartenAC, de LeonMJ, McHughP, MielkeMM, MolinuevoJL, MosconiL, OsorioRS, PerrotingA, PetersenRC, RabinLA, RamiL, ReisbergB, RentzDM, SachdevPS, de la SayetteV, SaykinAJ, ScheltensP, ShulmanMB, SlavinMJ, SperlingRA, StewartR, UspenskayaO, VellasB, VisserPJ, WagnerM, Subjective Cognitive Decline Initiative (SCD-I) Working, Group (2014) A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimers Dement10, 844–852.
11.
MarkRE, SitskoornMM (2013) Are subjective cognitive complaints relevant in preclinical Alzheimer’s disease? A review and guidelines for healthcare professionals. Rev Clin Gerontol23, 61–74.
12.
TandetnikC, FarrellMT, CaryMS, CinesS, EmraniS, KarlawishJ, CosentinoS (2015) Ascertaining subjective cognitive decline: A comon of approaches and evidence for using an age-anchored reference group.S43-S. J Alzheimers Dis48, 55–paris.
13.
AmariglioRE, BeckerJA, CarmasinJ, WadsworthLP, LoriusN, SullivanC, MayeJE, GidicsinC, PepinLC, SperlingRA, KA, RentzDM (2012) Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. Neuropsychologia50, 2880–2886.
14.
PerrotinA, MorminoEC, MadisonCM, HayengaAO, JagustWG (2012) Subjective cognition and amyloid deposition imaging: A Pittsburgh Compound B positron emission tomography study in normal elderly individuals. Arch Neurol69, 223–229.
SaykinAJ, WishartHA, RabinLA, SantulliRB, FlashmanLA, WestJD, McHughTL, MamourianAC (2006) Older adults with cognitive complaints show brain atrophy similar to that of amnestic MCI. Neurology67, 834–842.
WangY, RisacherSL, WestJD, McDonaldBC, MageeTR, FarlowMR, GaoS, O’NeillDP, SaykinAJ (2013) Altered default mode network connectivity in older adults with cognitive complaints and amnestic mild cognitive impairment. J Alzheimers Dis35, 751–760.
19.
JessenF, WieseB, BickelH, Eiffländer-GorferS, FuchsA, KaduszkiewiczH, KöhlerM, LuckT, MöschE, PentzekM, Riedel-HellerSG, WagnerM, Weyerer, MaierW, van den BusscheH, for the AgeCoDe Study, Group (2011) Prediction of dementia in primary care patients. PLoS One6, e16852.
20.
ReisbergB, ShulmanM, TorossianC, LengL, ZhuW (2010) Outcome over seven years of healthy adults with and without subjective cognitive impairment. Alzheimers Dement6, 11–24.
21.
BalashY, MordechovichM, ShabtaiH, GiladiN, GurevichT, KorczynAD (2013) Subjective memory complaints in elders: Depression, anxiety, or cognitive decline?Acta Neurol Scand127, 344–350.
22.
JormAF, ButterworthP, AnsteyKJ, ChristensenH, EastealS, MallerJ, MatherKA, TurakulovRI, WenW, SachdevP (2004) Memory complaints in a community sample aged 60-64 years: Associations with cognitive functioning, psychiatric symptoms, medical conditions, APOE genotype, hippocampus and amygdala volumes, and white-matter hyperintensities. Psychol Med34, 1495–1506.
23.
SlavinMJ, BrodatyH, KochanNA, CrawfordJD, TrollorJN, DraperB, SachdevPS (2010) Prevalence and predictors of “subjective cognitive complaints” in the Sydney Memory and Ageing Study. Am J Geriatr Psychiatry18, 701–710.
24.
BuckleyR, SalingMM, AmesD, RoweCC, LautenschlagerNT, MacaulaySL, MartinsRN, MastersCL, O’MearaT, SavageG, SzoekeC, VillemagneVL, EllisKA, and Australian Imaging Biomarkers and Lifestyle Study of Aging (AIBL) Research Group (2013) Factors affecting subjective memory complaints in the AIBL aging study: biomarkers, memory, affect, and age. Int Psychogeriatr25, 1307–1315.
25.
HollandsS, LimYY, BuckleyR, PietrzakRH, SnyderPJ, AmesD, EllisKA, HarringtonK, LautenschlagerN, MartinsRN, MastersCL, VillemagneVL, RoweCC, MaruffP, and for the AIBL Research Group (2015) Amyloid-β related memory decline is not associated with subjective or informant rated cognitive impairment in healthy adults. J Alzheimers Dis43, 677–686.
26.
JonkerC, GeerlingsMI, SchmandB (2010) Are memory complaints predictive for dementia? A review of clinical and population-based studies. Int J Geriatr Psychiatry15, 983–991.
27.
FarrellME, KennedyKM, RodrigueKM, WigGS, BischofGN, RieckJR, ChenX, FestiniSB, DevousMD, ParkDC (2016) Differentiating preclinical Alzheimer’s disease from normal aging: The effects of age and amyloid on cognitive decline over 3.5 years. Alzheimers Dement12, P3–272.
28.
GradyC (2012) The cognitive neuroscience of ageing. Nat Rev Neurosci13, 491–505.
WhalleyLJ, DearyIJ, AppletonCL, StarrJM (2004) Cognitive reserve and the neurobiology of cognitive aging. Ageing Res Rev3, 369–382.
31.
BuckleyRF, SalingMM, FrommannI, WolfsgruberS, WagnerM (2015) Subjective cognitive decline from a phenomenological perspective: A review of the qualitative literature. J Alzheimers Dis48, S125–S140.
32.
RabinLA, SmartCM, CranePK, AmariglioRE, BermanLM, BoadaM, BuckleyRF, ChételatG, DuboisB, EllisKA, GiffordKA, JeffersonAL, JessenF, KatzMJ, LiptonRB, LuckT, u, MaruffP, MielkeMM, MolinuevoJL, NaeemF, PerrotinA, PetersenR, RamiL, ReisbergB, RentzDM, Riedel-HellerSG, RisacherSL, RodriguezO, SachdevPS, SaykinAJ, SlavinMJ, SnitzBE, SperlingRA, TandetnikC, van der FlierWM, WagnerM, WolfsgruberS, theAlzheimer’s Disease Neuroimaging Initiative, SikkesSAM, and the Subjective Cognitive Decline Initiative (SCD-I)Working Group (2015) Subjective cognitive decline in older adults: An overview of self-report measures usedacross 19 international research studies. J Alzheimers Dis48, S63–S86.
33.
La JoieR, PerrotinA, EgretS, PasquierF, TomadessoC, MezengeF, DesgrangesB, de la SayetteV, ChételatG (2016) Qualitative and quantitative assessment of self-reported cognitive difficulties in nondemented elders:Association with medical help seeking, cognitive deficits and β-amyloid imaging. Alzheimers Dement5, 23–34.
34.
McNairDM, KahnRJ (1983) Self-assessment of cognitive deficits. In Assessment in Geriatric Psychopharmacology, CrookT, FerrisS, BartusR, eds. Mark Powley Associates, New Canaan, pp. 119–136.
FolsteinM, FolsteinS, MchughP (1975) “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician. J Psychiatry Res12, 189–198.
38.
JackCR, KnopmanDS, ChételatG, DicksonD, FaganAM, FrisoniGB, JagustW, MorminoE, PetersenRC, SperlingRA, van der FlierWM, VillemagneVL, VlasserP, VosSJB (2016) Suspected non-Alzheimer disease pathophysiology-concept and controversy. Nat Rev Neurol12, 117–124.
39.
JackCR, KnopmanDS, WeigandSD, WisteHJ, VemuriP, LoweV, KantarciK, GunterJL, Senjem, IvnikRJ, RobertsRO, RoccaWA, BoeveBF, PetersenRC (2012) An operational approach to National Institute on Aging-Alzheimer’s Association criteria for preclinical Alzheimer disease. Ann Neurol71, 765–775.
40.
RamiL, BoschB, Sanchez-ValleR, MolinuevoJL (2010) The memory alteration test (M@T) discriminates between subjective memory complaints, mild cognitive impairment and Alzheimer’s disease. Arch Gerontol Geriatr50, 171–174.
WarringtonE, JamesM (1991) Visual Object and Space Perception Battery (VOSP), Thames Valley Test Co, Bury St. Edmunds.
44.
ReitanR (1994) Trail Making Test (TMT). Reitan Neuropsychology Laboratory, USA.
45.
BentonAL, HamsherK (1976) Multilingual Aphasia Examination Manual, University of Iowa, Iowa City.
46.
GroberE, Ocepek-WeliksonK, TeresiJA (2009) The Free and Cued Selective Reminding Test: Evidence of psychometric adequacy. Psychol Sci Q51, 266–282.
47.
StroopJ (1935) Studies of interference in serial verbal reactions. J Exp Psychol28, 643–662.
48.
ZigmondA, SnaithR (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand67, 361–370.
49.
TrevesIA, VerchovskyR, KlimovitzkyS, KorczynAD (2005) Incidence of dementia in patients with subjective memory complaints. Int Psychogeriatr17, 265–273.
RabinLA, WangC, KatzMJ, DerbyCA, BuschkeH, LiptonRB (2012) Predicting Alzheimer’s disease: Neuropsychological tests, self-reports, and informant reports of cognitive difficulties. J Am Geriatr Soc60, 1128–1134.
52.
MichaelsonDM (2014) APOE epsilon4: The most prevalent yet understudied risk factor for Alzheimer’s disease. Alzheimers Dement10, 861–868.
53.
BjellandI, DahlAA, TangenT, NeckelmannD (2002) The validity of the Hospital Anxiety and Depression Scale An updated literature review. J Psychosom Res52, 69–77.
54.
BernardC, HelmerC, DilharreguyB, AmievaH, AuriacombeS, DartiguesJF, AllardM, CathelineG (2014) Time course of brain volume changes in the preclinical phase of Alzheimer’s disease. Alzheimers Dement10, 143–151.
55.
DickersonBC, BakkourA, SalatDH, FeczkoE, PachecoJ, GreveDN, GrodsteinF, WrightCI, BlackerD, RosasHD, SperlingRA, AtriA, GrowdonJH, HymanBT, MorrisJC, FischlB, BucknerRL (2009) The cortical signature of Alzheimer’s disease: Regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex19, 497–510.
56.
KimJ, KimYH, LeeJH (2013) Hippocampus-precuneus functional connectivity as an early sign of Alzheimer’s disease: A preliminary study using structural and functional magnetic resonance imaging data. Brain Res1495, 18–29.
57.
TwamleyEW, Legendre-RopackiSA, BondiMW (2006) Neuropsychological and neuroimaging changes in preclinical Alzheimer’s disease. J Int Neuropsychol Soc12, 707–735.
58.
GreiciusMD, KrasnowB, Boyett-AndersonJM, EliezS, SchatzbergAF, ReissAL (2003) Regional analysis of hippocampal activation during memory encoding and retrieval: FMRI study. Hippocampus174, 164–174.
59.
SquireLR, StarkCEL, ClarkRE (2004) The medial temporal lobe. Annu Rev Neurosci27, 279–306.
HeddenT, OhH, YoungerAP, PatelTA (2013) Ovid: Meta-analysis of amyloid-cognition relations in cognitively normal older adults. Neurology89, 1341–1348.
62.
LinL, FergusI (2008) Aging and memory: A cognitive approach. Can J Psychiatry53, 346–353.
63.
SullivanMO (2017) Patterns of brain atrophy on magnetic resonance imaging and the boundary between ageing and Alzheimer’s disease. Rev Clin Gerontol19, 295–307.
64.
MaruszakA, ThuretS (2014) Why looking at the whole hippocampus is not enough: A critical role for anteroposterior axis, subfield and activation analyses to enhance predictive value of hippocampal changes for Alzheimer’s disease diagnosis. Front Cell Neurosci8, 1–11.
65.
JerniganTL, ArchibaldSL, Fennema-NotestineC, GamstAC, StoutJC, BonnerJ, HesselinkJR (2001) Effects of age on tissues and regions of the cerebrum and cerebellum. Neurobiol Aging22, 581–594.
66.
WalhovdKB, FjellAM, ReinvangI, LundervoldA, DaleAM, EilertsenDE, QuinnBT, SalatD, MakrisN, FischlB (2005) Effects of age onvolumes of cortex, white matter and subcortical structures. Neurobiol Aging26, 1261–1270.
67.
MattssonN, InselPS, NoshenyR, TosunD, TrojanowskiJQ, ShawLM, JackCRJr, DonohueMC, WeinerMW, for the Alzheimer’s Disease Neuroimaging Initiative (2014) Emerging β-amyloid pathology and accelerated cortical atrophy. JAMA Neurol71, 725–734.
68.
DesikanRS, SabuncuMR, SchmanskyNJ, ReuterM, CabralHJ, HessCP, WeinerMW, BiffiA, AndersonCD, RosandJ, SalatDH, KemperTL, DaleAM, SperlingRA, FischlB, the Alzheimer’s Disease Neuroimaging Initiative (2010) Selective disruption of the cerebral neocortex in Alzheimer’s disease. PloS One5, e12853.
69.
BeckerJA, HeddenT, CarmasinJ, MayeJ, RentzDM, PutchaD, FischlB, GreveDN, MarshallGA, SallowayS, MarksD, BucknerRL, SperlingRA, JohnsonKA (2011) Amyloid-β associated cortical thinning in clinically normal elderly. Ann Neurol69, 1032–1042.
70.
VlassenkoAG, MintunMA, XiongC, ShelineYI, GoateAM, BenzingerTLS, MorrisJC (2011) Amyloid-beta plaque growth in cognitively normal adults: Longitudinal [11C] Pittsburgh compound B data. Ann Neurol70, 857–861.
71.
HarringtonMG, ChiangJ, PogodaJM, GomezM, ThomasK, MarionSD, MillerKJ, SiddarthP, YiX, ZhouF, LeeS, ArakakiX, CowanRP, TranT, CharleswellC, RossBD, FontehAN (2013) Executive function changes before memory in preclinical Alzheimer’s pathology: A prospective, cross-sectional, case control study. PLoS One8, e79378.
72.
Van HartenAC, SmitsLL, TeunissenCE, VisserPJ, KoeneT, BlankensteinMA, ScheltensP, van der FlierWM (2013) Preclinical AD predicts decline in memory and executive functions in subjective complaints. Neurology81, 1409–1416.
73.
GroberE, HallCB, LiptonRB, ZondermanAB, ResnickSM, KawasC (2008) Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer’s disease. JINS14, 266–278.
74.
SchröderJ, WendelsteinB, FelderE (2011) Language in the preclinical stage of Alzheimer’s Disease: Content and complexity in biographical narratives. Alzheimers Dement7, S602.
75.
CuetosF, Arango-LasprillaJC, UribeC, ValenciaC, LoperaF (2007) Linguistic changes in verbal expression: A preclinical marker of Alzheimer’s disease. J Int Neuropsychol Soc13, 433–439.
76.
JonesS, LaukkaEJ, BäckmanL (2006) Differential verbal fluency deficits in the preclinical stage of Alzheimer’s disease and vascular dementia. Cortex42, 346–355.
77.
PappKV, MorminoEC, AmariglioRE, MunroC, DagleyA, SchultzAP, JohnsonKA, SperlingRA, RentzDM (2016) Biomarker validation of a decline in semantic processing in preclinical Alzheimer’s disease. Neuropsychology30, 624–630.
78.
MartinA, ChaoLL (2001) Semantic memory and the brain: Structure androcesses. Curr Opin Neurobiol11, 194–201.
79.
JoubertS, BrambatiSM, AnsadoJ, BarbeauEJ, FelicianO, DidicM, LacombeJ, GodlsteinR, ChayerC, KergoatMJ (2010) The cognitive and neural expression of semantic memory impairment in mild cognitive impairment and early Alzheimer’s disease. Neuropsychologia48, 978–988.
80.
MillerKJ, RogersSA, SiddarthP, SmallGW (2005) Object naming and semantic fluency among individuals with genetic risk for Alzheimer’s disease. Int J Geriatr Psychiatry20, 128–136.
81.
WierengaCE, StrickerNH, McCauleyA, SimmonsA, JakAJ, ChangY, Delano-WoodL, BangenKJ, SalmonDP, BondiMW (2010) Increasedfunctional brain response during word retrieval in cognitivelyintact older adults at genetic risk for Alzheimer’s disease. Neuroimage51, 1222–1233.
82.
FonsecaAT, GuedjE, AlarioF, LaguittonV, MundlerO, ChauvelP, Liegeois-ChauvelC (2009) Brain regions underlying word finding difficulties in temporal lobe epilepsy. Brain132, 2772–2784.
83.
WierengaCE, BenjaminM, GopinathK, PerlsteinWM, LeonardCM, GonzalezLJ, ConwayTM, AllisonCM, BriggsR, CrossonB (2008) Age-related changes in word retrieval: Role of bilateral frontal and subcortical networks. Neurobiol Aging29, 436–451.
84.
AdlamAL, BozeatS, ArnoldR, WatsonP, HodgesJR (2006) Semantic knowledge in mild cognitive impairment and mild Alzheimer’s disease. Cortex42, 675–684.
85.
TsantaliE, EconomidisD, TsolakiM (2013) Could language deficits really differentiate Mild Cognitive Impairment (MCI) from mild Alzheimer’s disease?Arch Gerontol Geriatr57, 263–270.
86.
Lambon RalphMA, PattersonK, GrahamN, DawsonK, HodgesJR (2003) Homogeneity and heterogeneity in mild cognitive impairment and Alzheimer’s disease: A cross-sectional and longitudinal study of 55 cases. Brain126, 2350–2362.
87.
ChapmanSB, ZientzJ, WeinerM, RosenbergR, FrawleyW, BurnsMH (2002) Discourse changes in early Alzheimer’s disease, mild cognitive impairment and normal aging. Alzheimer Dis Assoc Disord16, 177–186.
88.
GordonBA, ZacksJM, BlazeyT, MorrisJC, FaganAM, HoltzmanDM, BalotaDA (2015) Task-evoked fMRI changes in attention networks are associated with preclinical Alzheimer’s disease biomarkers. Neurobiol Aging36, 1771–1779.
89.
BalotaDA, TseC, HutchisonKA, SpielerDH, JanetM, MorrisJC (2010) Predicting conversion to dementia of the Alzheimer type in a healthy control sample: The powers of errors in Stroop Color Naming. Pyschol Aging25, 208–218.
90.
BalotaDA, FaustME (2001) Attention in dementia of the Alzheimer’s type. In Handbook of Neuropsychology,BollerF, CappaS, eds. Elsevier Science, New York, pp. 51–80.
